



# LKT Laboratories, Inc.

## Hexamethylene Bisacetamide

Phone: 888-558-5227  
651-644-8424  
Fax: 888-558-7329  
Email: [getinfo@lctlabs.com](mailto:getinfo@lctlabs.com)  
Web: [lctlabs.com](http://lctlabs.com)

### Product Information

**Product ID** H1892

**CAS No.** 3073-59-4

**Chemical Name** N,N'-Hexamethylene (bis)acetamide

**Synonym** N,N'-Diacetyl-1,6-hexanediamine, HMBA


**Formula** C<sub>10</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub>

**Formula Wt.** 200.28

**Melting Point** 128-129 °C

**Purity** ≥98%

**Solubility** Soluble in water or ethanol.



### Pricing and Availability

**Bulk quantities available upon request**

Product ID	Size	List Price
H1892	25 g	\$63.70
H1892	50 g	\$101.60

**Store Temp** Ambient

**Ship Temp** Ambient

**Description** Hexamethylene bisacetamide (HMBA) activates hexamethylene bisacetamide-inducible protein 1 (HEXIM1), inhibiting transcription elongation factor b (P-TEFb), a regulator of RNA polymerase II and mRNA synthesis. HMBA exhibits anticancer activity and is used to induce cellular differentiation and apoptosis in cancer cells. HMBA also inhibits activation of NF-κB, Akt, and ERK.

**References** Lew QJ, Chia YL, Chu KL, et al. Identification of HEXIM1 as a positive regulator of p53. J Biol Chem. 2012 Oct 19;287(43):36443-54. PMID: 22948151.

Dey A, Wong E, Kua N, et al. Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy. Cell Cycle. 2008 Dec;7(23):3759-67. PMID: 19029824.

Zhang Z, Liong EC, Lau TY, et al. Induction of apoptosis by hexamethylene bisacetamide is p53-dependent associated with telomerase activity but not with terminal differentiation. Int J Oncol. 2000 May;16(5):887-92. PMID: 10762623.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.